Skip to content

ArriVent BioPharma, Inc. AVBP Investing Cash Flow

Investing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$1.04B-250%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$38.39M-59.2%
Nuvation Bio logo
Nuvation BioNUVB
-$43.64M-181%
Immunome logo
ImmunomeIMNM
-$12.02M-336%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$114M+256%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$243.83M-812%

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.49B+62.1%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s investing cash flow?
ArriVent BioPharma, Inc. (AVBP) reported investing cash flow of $3.58M in Q1 2026.
How has ArriVent BioPharma, Inc.'s investing cash flow changed year-over-year?
ArriVent BioPharma, Inc.'s investing cash flow decreased by 90.3% year-over-year, from $36.82M to $3.58M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.